Shasun Chemicals signs agreement with Lundbeck

3483 Investors following Shasun Pharma. Share this News with them.

0

Like this story, share it with millions of investors on M3

Shasun Chemicals signs agreement with Lundbeck

Shasun Chemicals signs technology licensing agreement with Lundbeck

Post your opinion here

 

0

Tweet

Share on Tumblr

RELATED NEWS Shasun Chemicals receives approval for formulation facility Buy Shasun Chemicals at Rs 118 Shasun Chemicals has support at Rs 115: VK Sharma ALSO READ See latest News about Shasun Pharma See previous management interviews See what other Experts & Brokerages are saying about Shasun Pharma Shasun Pharma BSE | NSE 25/05/12 Are Mutual Funds betting on Shasun Pharma?

Shasun Chemicals & Drugs Ltd ; today announced that it's wholly-owned UK-subsidiary Shasun Pharma Solutions Ltd has entered into a non-exclusive licensing agreement with H Lundbeck A/S , a research based Danish company engaged in finding new drugs for treatment of CNS (Central Nervous System) disorders.

Under the terms of the agreement, Shasun Pharma grants H Lundbeck A/S the use of its proprietary cross-coupling technology (also known as Buchwald technology) to manufacture and commercialize new APIs (Active Pharmaceutical Ingredients). The Buchwald cross-coupling technology is one of the most referred to technologies in the pharmaceutical area allowing increasing complex new drugs to be manufactured in a more straightforward and economical way.

Commenting on the development, Dr. Michel Spagnol, Vice President, Lundbeck said, "Lundbeck will have access to one of the most powerful cross-coupling technologies allowing them to speed up the development of new drugs while reducing the cost of manufacture."

Mr. Govindarajan, CEO and MD of Shasun Chemicals & Drugs added, "This is yet another example of Shasun's flexibility in dealing with the management of its Intellectual Property and making sure that it services its customer first!"

Sourced From: Adfactors Public Relations Pvt Ltd